Opinion
Video
Author(s):
The expert panel concludes its discussion by providing key takeaways on the evolving bladder cancer treatment landscape following ESMO 2023.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Survey: New NMIBC treatments face slow uptake
Dr. Schwen on focal therapies for prostate cancer
NIAGARA: ctDNA analysis highlights durvalumab’s impact in MIBC
Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care
EFS benefit is seen with sasanlimab in CIS and T1 NMIBC
Interim ENLIGHTED data show promise for padeliporfin VTP therapy in UTUC
Lower-dose abiraterone offers viable alternative to standard-dose for mCRPC
Long-term data support radium-223 safety in mCRPC
RCT compares platinum/5-FU, platinum/paclitaxel in high-risk penile cancer